TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moderna ( (MRNA) ) has provided an update.
On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where two proposals were approved. The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of the meeting to a later date if necessary, to ensure sufficient votes for the stock option exchange program. Both proposals were passed with no broker non-votes recorded.
The most recent analyst rating on (MRNA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
Moderna’s overall stock score reflects significant financial challenges, including declining revenues and profitability. Technical analysis indicates weak momentum, and valuation concerns persist with a negative P/E ratio. However, strategic cost reductions and partnerships provide some optimism for future growth.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna, Inc. operates in the biotechnology industry, focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company is known for its work in developing vaccines, including its COVID-19 vaccine, and is a significant player in the pharmaceutical market.
Average Trading Volume: 11,252,801
Technical Sentiment Signal: Sell
Current Market Cap: $10.44B
Learn more about MRNA stock on TipRanks’ Stock Analysis page.